Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Virchows Archiv
Erschienen in: Virchows Archiv 3/2018

11.07.2018 | Review and Perspectives

Primary small bowel adenomas and adenocarcinomas—recent advances

verfasst von: Aoife Maguire, Kieran Sheahan

Erschienen in: Virchows Archiv | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

The small intestine represents 75% of the length and 90% of the absorptive surface area of the gastrointestinal tract (GIT), yet only 2% of digestive system cancers occur at this site. Adenocarcinoma accounts for half of small bowel malignancies. There have been a number of important recent advances in our understanding, classification and treatment of small bowel tumours. Over recent years, ampullary tumours have become recognised as a form of small bowel carcinoma, distinct from head of pancreas and lower biliary tract tumours. This is reflected in separate TNM systems and increasing interest in separating intestinal from pancreatobiliary subtypes. The recognition of the importance of microsatellite (MSI) status and the advent of molecular pathology has also changed our approach to these neoplasms.
Literatur
1.
Schottenfeld D, Beebe-Dimmer JL, Vigneau FD (2009) The epidemiology and pathogenesis of neoplasia in the small intestine. Ann Epidemiol 19:58–69CrossRefPubMedPubMedCentral
2.
Bilimoria KY, Bentrem DJ, Wayne JD, Ko CY, Bennett CL, Talamonti MS (2009) Small bowel cancer in the United States: changes in epidemiology, treatment and survival over the last 20 years. Ann Surg 249:63–71CrossRefPubMed
3.
Genta RM, Feagins LA (2013) Advanced precancerous lesions in the small bowel mucosa. Best Pract Res Clin Gastroenterol 27:225–233CrossRefPubMed
4.
Perzin KH, Bridge MF (1981) Adenomas of the small intestine: a clinicopathologic review of 51 cases and a study of their relationship to carcinoma. Cancer 48:799–819CrossRefPubMed
5.
Brosens LA, Keller JJ, Offerhaus GJ, Goggins M, Giardiello FM (2005) Prevention and management of duodenal polyps in familial adenomatous polyposis. Gut 54:1034–1043CrossRefPubMedPubMedCentral
6.
Rosty C, Campbell C, Clendenning M, Bettington M, Buchanan DD, Brown IS (2014) Do serrated neoplasms of the small intestine represent a distinctive entity? Pathological findings and molecular alterations in a series of 13 cases. Histopathology 66:333–342
7.
Ushiku T, Arnason T, Fukayama M, Lauwers GY (2014) Extra-ampullary duodenal adenocarcinoma. Am J Surg Pathol 38:1484–1493CrossRefPubMed
8.
Kadmon M, Tandara A, Herfarth C (2001) Duodenal adenomatosis in familial adenomatous polyposis coli. A review of the literature and results from the Heidelberg polyposis register. Int J Color Dis 16:63–75CrossRef
9.
Agaimy A, Vassos N, Croner RS (2012) Gastrointestinal manifestations of neurofibromatosis type 1 (Recklinghausen’s disease): clinicopathological spectrum with pathogenetic considerations. Int J Clin Exp Pathol 5:852–862 ReviewPubMedPubMedCentral
10.
11.
Haselkorn T, Whittemore AS, Lilienfeld DE (2005) Incidence of small bowel cancer in the United States and worldwide: geographic, temporal, and racial differences. Cancer Causes Control 16:781–787CrossRefPubMed
12.
Arber N, Neugut AI, Weinstein IB, Holt P (1997) Molecular genetics of small bowel cancer. Cancer Epidemiol Biomark Prev 6:745–748
13.
Sellner F (1990) Investigations on the significance of the adenoma-carcinoma sequence in the small bowel. Cancer 66:702–715CrossRefPubMed
14.
Delaunoit T, Neczyporenko F, Limburg PJ, Erlichman C (2005) Pathogenesis and risk factors of small bowel adenocarcinoma: a colorectal cancer sibling? Am J Gastroenterol 100:703–710CrossRefPubMed
15.
Chen CC, Neugut AI, Rotterdam H (1994) Risk factors for adenocarcinomas and malignant carcinoids of the small intestine: preliminary findings. Cancer Epidemiol Biomark Prev 3:205–207
16.
17.
18.
Sanders LM, Henderson CE, Hong MY, Barhoumi R, Burghardt RC, Carroll RJ, Turner ND, Chapkin RS, Lupton JR (2004) Pro-oxidant environment of the colon compared to the small intestine may contribute to greater cancer susceptibility. Cancer Lett 208:155–161CrossRefPubMed
19.
DiSario JA, Burt RW, Vargas H, McWhorter WP (1994) Small bowel cancer: epidemiological and clinical characteristics from a population-based registry. Am J Gastroenterol 89:699–701PubMed
20.
Ciresi DL, Scholten DJ (1995) The continuing clinical dilemma of primary tumors of the small intestine. Am Surg 61:698–702 discussion 702-693PubMed
21.
Schirmacher P, Buchler MW (2008) Ampullary adenocarcinoma—differentiation matters. BMC Cancer 8(251)
22.
Schwameis K, Schoppmann SF, Stift J, Schwameis M, Stift A (2014) Small bowel adenocarcinoma—terra incognita: a demand for cross-national pooling of data. Oncol Lett 7:1613–1617CrossRefPubMedPubMedCentral
23.
24.
Ross RK, Hartnett NM, Bernstein L, Henderson BE (1991) Epidemiology of adenocarcinomas of the small intestine: is bile a small bowel carcinogen? Br J Cancer 63:143–145CrossRefPubMedPubMedCentral
25.
Hatzaras I, Palesty JA, Abir F, Sullivan P, Kozol RA, Dudrick SJ, Longo WE (2007) Small-bowel tumors: epidemiologic and clinical characteristics of 1260 cases from the Connecticut Tumor Registry. Arch Surg 142:229–235CrossRefPubMed
26.
Bauer RL, Palmer ML, Bauer AM, Nava HR, Douglass HO, Jr. (1994) Adenocarcinoma of the small intestine: 21-year review of diagnosis, treatment, and prognosis. Ann Surg Oncol 1;183–188
27.
Dabaja BS, Suki D, Pro B, Bonnen M, Ajani J (2004) Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer 101:518–526CrossRefPubMed
28.
Talamonti MS, Goetz LH, Rao S, Joehl RJ (2002) Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management. Arch Surg 137:564–570 discussion 570-561CrossRefPubMed
29.
Howe JR, Karnell LH, Menck HR, Scott-Conner C (1999) The American College of Surgeons commission on cancer and the American Cancer Society. Adenocarcinoma of the small bowel: review of the national cancer data base, 1985-1995. Cancer 86:2693–2706CrossRefPubMed
30.
Overman MJ, Hu CY, Wolff RA, Chang GJ (2010) Prognostic value of lymph node evaluation in small bowel adenocarcinoma: analysis of the surveillance, epidemiology, and end results database. Cancer 116:5374–5382CrossRefPubMed
31.
Balmforth DC, Phillips RK, Clark SK (2012) Advanced duodenal disease in familial adenomatous polyposis: how frequently should patients be followed up after successful therapy? Familial Cancer 11:553–557CrossRefPubMed
32.
Spigelman AD, Williams CB, Talbot IC, Domizio P, Phillips RK (1989) Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Lancet 2:783–785CrossRefPubMed
33.
34.
Egan L, D’Inca R, Jess T, Pellino G, Carbonnel F, Bokemeyer B, Harbord M, Nunes P, van der Woude J, Selvaggi F, Triantafillidis J (2014) Non-colorectal intestinal tract carcinomas in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (ii). J Crohn’s Colitis 8:19–30CrossRef
35.
Svrcek M, Piton G, Cosnes J, Beaugerie L, Vermeire S, Geboes K, Lemoine A, Cervera P, el-Murr N, Dumont S, Scriva A, Lascols O, Ardizzone S, Fociani P, Savoye G, le Pessot F, Novacek G, Wrba F, Colombel JF, Leteurtre E, Bouhnik Y, Cazals-Hatem D, Cadiot G, Diebold MD, Rahier JF, Delos M, Fléjou JF, Carbonnel F (2014) Small bowel adenocarcinomas complicating Crohn’s disease are associated with dysplasia: a pathological and molecular study. Inflamm Bowel Dis 20:1584–1592CrossRefPubMed
36.
Piton G, Cosnes J, Monnet E, Beaugerie L, Seksik P, Savoye G, Cadiot G, Flourie B, Capelle P, Marteau P, Lemann M, Colombel JF, Khouri E, Bonaz B, Carbonnel F (2008) Risk factors associated with small bowel adenocarcinoma in Crohn’s disease: a case-control study. Am J Gastroenterol 103:1730–1736CrossRefPubMed
37.
von Roon AC, Reese G, Teare J, Constantinides V, Darzi AW, Tekkis PP (2007) The risk of cancer in patients with Crohn’s disease. Dis Colon Rectum 50:839–855CrossRef
38.
Canavan C, Abrams KR, Mayberry J (2006) Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn’s disease. Aliment Pharmacol Ther 23:1097–1104CrossRefPubMed
39.
Jess T, Gamborg M, Matzen P, Munkholm P, Sorensen TI (2005) Increased risk of intestinal cancer in Crohn’s disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol 100:2724–2729CrossRefPubMed
40.
Askling J, Linet M, Gridley G, Halstensen TS, Ekstrom K, Ekbom A (2002) Cancer incidence in a population-based cohort of individuals hospitalized with celiac disease or dermatitis herpetiformis. Gastroenterology 123:1428–1435CrossRefPubMed
41.
Howdle PD, Jalal PK, Holmes GK, Houlston RS (2003) Primary small-bowel malignancy in the UK and its association with coeliac disease. QJM 96:345–353CrossRefPubMed
42.
Nicholl MB, Ahuja V, Conway WC, Vu VD, Sim MS, Singh G (2010) Small bowel adenocarcinoma: understaged and undertreated? Ann Surg Oncol 17:2728–2732CrossRefPubMed
43.
Koo DH, Yun SC, Hong YS, Ryu MH, Lee JL, Chang HM, Ryoo BY, Kang YK, Kim TW (2011) Systemic chemotherapy for treatment of advanced small bowel adenocarcinoma with prognostic factor analysis: retrospective study. BMC Cancer 11:205
44.
Zaanan A, Costes L, Gauthier M, Malka D, Locher C, Mitry E, Tougeron D, Lecomte T, Gornet JM, Sobhani I, Moulin V, Afchain P, Taieb J, Bonnetain F, Aparicio T (2010) Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study. Ann Oncol 21:1786–1793CrossRefPubMed
45.
Khan K, Peckitt C, Sclafani F, Watkins D, Rao S, Starling N, Jain V, Trivedi S, Stanway S, Cunningham D, Chau I (2015) Prognostic factors and treatment outcomes in patients with small bowel adenocarcinoma (SBA): the Royal Marsden Hospital (RMH) experience. BMC Cancer 15(15):15CrossRefPubMedPubMedCentral
46.
Overman MJ, Kopetz S, Lin E, Abbruzzese JL, Wolff RA (2010) Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. Acta Oncol 49:474–479CrossRefPubMed
47.
Mizushima T, Tamagawa H, Mishima H et al (2013) The effects of chemotherapy on primary small bowel cancer: a retrospective multicenter observational study in Japan. Mol Clin Oncol 1:820–824CrossRefPubMedPubMedCentral
48.
Guo XC, Mao ZY, Su D, Wang LJ, Zhang TT, Bai L (2014) Retrospective analysis of 119 small bowel adenocarcinoma in Chinese patients. Cancer Investig 32:178–183CrossRef
49.
Koo DH, Yun SC, Hong YS, Ryu MH, Lee JL, Chang HM, Kang YK, Kim SC, Han DJ, Lee YJ, Kim TW (2011) Adjuvant chemotherapy for small bowel adenocarcinoma after curative surgery. Oncology (Williston Park) 80:208–213CrossRef
50.
Halfdanarson TR, McWilliams RR, Donohue JH, Quevedo JF (2010) A single-institution experience with 491 cases of small bowel adenocarcinoma. Am J Surg 199:797–803CrossRefPubMed
51.
Overman MJ (2013) Rare but real: management of small bowel adenocarcinoma. Am Soc Clin Oncol Educ Book 189–193
52.
Bogaerts J, Sydes MR, Keat N et al (2014) Clinical trial designs for rare diseases: studies developed and discussed by the international rare cancers initiative. Eur J Cancer 51:271–281CrossRefPubMed
53.
Valsangkar NP, Ingkakul T, Correa-Gallego C, Mino-Kenudson M, Masia R, Lillemoe KD, Castillo CFD, Warshaw AL, Liss AS, Thayer SP (2015) Survival in ampullary cancer: potential role of different KRAS mutations. Surgery 157:260–268CrossRefPubMedPubMedCentral
54.
Kohler I, Jacob D, Budzies J, Lehmann A, Weichert W, Schulz S, Neuhaus P, Röcken C (2011) Phenotypic and genotypic characterization of carcinomas of the papilla of vater has prognostic and putative therapeutic implications. Am J Clin Pathol 135:202–211CrossRefPubMed
55.
Schultz NA, Roslind A, Christensen IJ, Horn T, Høgdall E, Pedersen LN, Kruhøffer M, Burcharth F, Wøjdemann M, Johansen JS (2012) Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas. Pancreas 41:759–766PubMed
56.
Blaker H, von Herbay A, Penzel R, Gross S, Otto HF (2002) Genetics of adenocarcinomas of the small intestine: frequent deletions at chromosome 18q and mutations of the SMAD4 gene. Oncogene 21(1):158–164CrossRefPubMed
57.
Wheeler JM, Warren BF, Mortensen NJ, Kim HC, Biddolph SC, Elia G, Beck NE, Williams GT, Shepherd NA, Bateman AC, Bodmer WF (2002) An insight into the genetic pathway of adenocarcinoma of the small intestine. Gut 50(2):218–223CrossRefPubMedPubMedCentral
58.
Schrock AB, Devoe CE, McWilliams R, Sun J, Aparicio T, Stephens PJ, Ross JS, Wilson R, Miller VA, Ali SM, Overman MJ (2017) Genomic profiling of small-bowel adenocarcinoma. JAMA Oncol 3:1546–1553CrossRefPubMed
59.
Laforest A, Aparicio T, Zaanan A, Silva FP, Didelot A, Desbeaux A, le Corre D, Benhaim L, Pallier K, Aust D, Pistorius S, Blons H, Svrcek M, Laurent-Puig P (2014) ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma. Eur J Cancer 50:1740–1746CrossRefPubMed
60.
61.
Planck M, Ericson K, Piotrowska Z, Halvarsson B, Rambech E, Nilbert M (2003) Microsatellite instability and expression of MLH1 and MSH2 in carcinomas of the small intestine. Cancer 97:1551–1557CrossRefPubMed
62.
Brueckl WM, Heinze E, Milsmann C, Wein A, Koebnick C, Jung A, Croner RS, Brabletz T, Günther K, Kirchner T, Hahn EG, Hohenberger W, Becker H, Reingruber B (2004) Prognostic significance of microsatellite instability in curatively resected adenocarcinoma of the small intestine. Cancer Lett 203:181–190CrossRefPubMed
63.
Martin JA, Haber GB (2003) Ampullary adenoma: clinical manifestations, diagnosis, and treatment. Gastrointest Endosc Clin N Am 13:649–669CrossRefPubMed
64.
Patel R, Varadarajulu S, Wilcox CM (2012) Endoscopic ampullectomy: techniques and outcomes. J Clin Gastroenterol 46:8–15CrossRefPubMed
65.
Cheng CL, Sherman S, Fogel EL, McHenry L, Watkins JL, Fukushima T, Howard TJ, Lazzell-Pannell L, Lehman GA (2004) Endoscopic snare papillectomy for tumors of the duodenal papillae. Gastrointest Endosc 60:757–764CrossRefPubMed
66.
Bellizi et al (2009) The assessmentof specimens procured by endoscopic ampullectomy. Am J Clin Path 132:506–531CrossRef
67.
Han J, Kim MH (2006) Endoscopic papillectomy for adenomas of the major duodenal papilla (with video). Gastrointest Endosc 63:292–301CrossRefPubMed
68.
Yamaguchi K, Enjoji M, Kitamura K (1990) Endoscopic biopsy has limited accuracy in diagnosis of ampullary tumors. Gastrointest Endosc 36:588–592CrossRefPubMed
69.
Kahaleh M, Shami VM, Brock A, Conaway MR, Yoshida C, Moskaluk CA, Adams RB, Tokar J, Yeaton P (2004) Factors predictive of malignancy and endoscopic resectability in ampullary neoplasia. Am J Gastroenterol 99:2335–2339CrossRefPubMed
70.
71.
Ahn DW, Ryu JK, Kim J, Yoon WJ, Lee SH, Kim YT, Yoon YB (2013) Endoscopic papillectomy for benign ampullary neoplasms: how can treatment outcome be predicted? Gut Liver 7:239–245CrossRefPubMedPubMedCentral
72.
Azih LC, Broussard BL, Phadnis MA, Heslin MJ, Eloubeidi MA, Varadarajulu S, Arnoletti JP (2013) Endoscopic ultrasound evaluation in the surgical treatment of duodenal and peri-ampullary adenomas. World J Gastroenterol 19:511–515CrossRefPubMedPubMedCentral
73.
Ang DC, Shia J, Tang LH, Katabi N, Klimstra DS (2014) The utility of immunohistochemistry in subtyping adenocarcinoma of the ampulla of vater. Am J Surg Pathol 38:1371–1379CrossRefPubMed
74.
Xue Y, Reid MD, Balci S, Quigley B, Muraki T, Memis B, Xia J, Hacihasanoglu E, Bedolla G, Pehlivanoglu B, Kim GE, Tajiri T, Ohike N, Aneja R, Krasinskas AM, Adsay V (2017) Immunohistochemical classification of ampullary carcinomas: critical reappraisal fails to confirm prognostic relevance for recently proposed panels, and highlights MUC5AC as a strong prognosticator. Am J Surg Pathol 41:865–876CrossRefPubMed
75.
Perysinakis I, Margaris I, Kouraklis G (2014) Ampullary cancer—a separate clinical entity? Histopathology 64:759–768CrossRefPubMed
76.
Adsay V, Ohike N, Tajiri T, Kim GE, Krasinskas A, Balci S, Bagci P, Basturk O, Bandyopadhyay S, Jang KT, Kooby DA, Maithel SK, Sarmiento J, Staley CA, Gonzalez RS, Kong SY, Goodman M (2012) Ampullary region carcinomas: definition and site specific classification with delineation of four clinicopathologically and prognostically distinct subsets in an analysis of 249 cases. Am J Surg Pathol 36:1592–1608CrossRefPubMed
77.
Aparicio T, Zaanan A, Svrcek M et al (2014) Small bowel adenocarcinoma: epidemiology, risk factors, diagnosis and treatment. Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 46:97–104CrossRef
78.
Bronsert P, Kohler I, Werner M, Makowiec F, Kuesters S, Hoeppner J, Hopt UT, Keck T, Bausch D, Wellner UF (2013) Intestinal-type of differentiation predicts favourable overall survival: confirmatory clinicopathological analysis of 198 periampullary adenocarcinomas of pancreatic, biliary, ampullary and duodenal origin. BMC Cancer 13(428)
79.
Carter JT, Grenert JP, Rubenstein L, Stewart L, Way LW (2008) Tumors of the ampulla of vater: histopathologic classification and predictors of survival. J Am Coll Surg 207:210–218CrossRefPubMed
80.
Chang DK, Jamieson NB, Johns AL, Scarlett CJ, Pajic M, Chou A, Pinese M, Humphris JL, Jones MD, Toon C, Nagrial AM, Chantrill LA, Chin VT, Pinho AV, Rooman I, Cowley MJ, Wu J, Mead RS, Colvin EK, Samra JS, Corbo V, Bassi C, Falconi M, Lawlor RT, Crippa S, Sperandio N, Bersani S, Dickson EJ, Mohamed MAA, Oien KA, Foulis AK, Musgrove EA, Sutherland RL, Kench JG, Carter CR, Gill AJ, Scarpa A, McKay CJ, Biankin AV (2013) Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. J Clin Oncol 31:1348–1356CrossRefPubMed
81.
Kim WS, Choi DW, Choi SH, Heo JS, You DD, Lee HG (2012) Clinical significance of pathologic subtype in curatively resected ampulla of vater cancer. J Surg Oncol 105:266–272CrossRefPubMed
82.
Kimura W, Futakawa N, Yamagata S, Wada Y, Kuroda A, Muto T, Esaki Y (1994) Different clinicopathologic findings in two histologic types of carcinoma of papilla of vater. Jpn J Cancer Res 85:161–166CrossRefPubMedPubMedCentral
83.
Roh YH, Kim YH, Lee HW, Kim SJ, Roh MS, Jeong JS, Jung GJ (2007) The clinicopathologic and immunohistochemical characteristics of ampulla of vater carcinoma: the intestinal type is associated with a better prognosis. Hepato-Gastroenterology 54:1641–1644PubMed
84.
Westgaard A, Pomianowska E, Clausen OP, Gladhaug IP (2013) Intestinal-type and pancreatobiliary-type adenocarcinomas: how does ampullary carcinoma differ from other periampullary malignancies? Ann Surg Oncol 20:430–439CrossRefPubMed
85.
Westgaard A, Tafjord S, Farstad IN, Cvancarova M, Eide TJ, Mathisen O, Clausen OPF, Gladhaug IP (2008) Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma. BMC Cancer 8(170)
86.
Zhou H, Schaefer N, Wolff M, Fischer HP (2004) Carcinoma of the ampulla of vater: comparative histologic/immunohistochemical classification and follow-up. Am J Surg Pathol 28:875–882CrossRefPubMed
87.
88.
Schueneman A, Goggins M, Ensor J, Saka B, Neishaboori N, Lee S, Maitra A, Varadhachary G, Rezaee N, Wolfgang C, Adsay V, Wang H, Overman MJ (2015) Validation of histomolecular classification utilizing histological subtype, muc1, and cdx2 for prognostication of resected ampullary adenocarcinoma. Br J Cancer 113:64–68CrossRefPubMedPubMedCentral
89.
Schiergens TS, Reu S, Neumann J, Renz BW, Niess H, Boeck S, Heinemann V, Bruns CJ, Jauch KW, Kleespies A (2015) Histomorphologic and molecular phenotypes predict gemcitabine response and overall survival in adenocarcinoma of the ampulla of vater. Surgery 158:151–161CrossRefPubMed
90.
Amin Mb, ed. AJCC cancer staging manual, 2017, Springer
91.
Balachandran P, Sikora SS, Kapoor S, Krishnani N, Kumar A, Saxena R, Kapoor VK (2006) Long-term survival and recurrence patterns in ampullary cancer. Pancreas 32:390–395CrossRefPubMed
92.
Hsu HP, Yang TM, Hsieh YH, Shan YS, Lin PW (2007) Predictors for patterns of failure after pancreaticoduodenectomy in ampullary cancer. Ann Surg Oncol 14:50–60CrossRefPubMed
93.
Hsu HP, Shan YS, Hsieh YH, Yang TM, Lin PW (2007) Predictors of recurrence after pancreaticoduodenectomy in ampullary cancer: comparison between non-, early and late recurrence. J Formos Med Assoc 106:432–443CrossRefPubMed
94.
Todoroki T, Koike N, Morishita Y, Kawamoto T, Ohkohchi N, Shoda J, Fukuda Y, Takahashi H (2003) Patterns and predictors of failure after curative resections of carcinoma of the ampulla of vater. Ann Surg Oncol 10:1176–1183CrossRefPubMed
95.
Kim RD, Kundhal PS, McGilvray ID et al (2006) Predictors of failure after pancreaticoduodenectomy for ampullary carcinoma. J Am Coll Surg 202:112–119CrossRefPubMed
96.
Winter JM, Cameron JL, Olino K, Herman JM, de Jong MC, Hruban RH, Wolfgang CL, Eckhauser F, Edil BH, Choti MA, Schulick RD, Pawlik TM (2010) Clinicopathologic analysis of ampullary neoplasms in 450 patients: implications for surgical strategy and long-term prognosis. J Gastrointes Surg 14:379–387CrossRef
97.
Woo SM, Ryu JK, Lee SH, Yoo JW, Park JK, Kim YT, Jang JY, Kim SW, Kang GH, Yoon YB (2007) Recurrence and prognostic factors of ampullary carcinoma after radical resection: comparison with distal extrahepatic cholangiocarcinoma. Ann Surg Oncol 14:3195–3201CrossRefPubMed
98.
Kang HJ, Eo SH, Kim SC, Park KM, Lee YJ, Lee SK, Yu E, Cho HJ, Hong SM (2014) Increased number of metastatic lymph nodes in adenocarcinoma of the ampulla of vater as a prognostic factor: a proposal of new nodal classification. Surgery 155:74–84CrossRefPubMed
99.
Ohike N, Coban I, Kim GE, Basturk O, Tajiri T, Krasinskas A, Bandyopadhyay S, Morohoshi T, Shimada Y, Kooby DA, Staley CA, Goodman M, Volkan Adsay N (2010) Tumor budding as a strong prognostic indicator in invasive ampullary adenocarcinomas. Am J Surg Pathol 34:1417–1424CrossRefPubMedPubMedCentral
100.
Bhatia S, Miller RC, Haddock MG, Donohue JH, Krishnan S (2006) Adjuvant therapy for ampullary carcinomas: the mayo clinic experience. Int J Radiat Oncol Biol Phys 66:514–519CrossRefPubMed
101.
Lee JH, Whittington R, Williams NN, Berry MF, Vaughn DJ, Haller DG, Rosato EF (2000) Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas. Int J Radiat Oncol Biol Phys 47:945–953CrossRefPubMed
102.
Kim K, Chie EK, Jang JY, Kim SW, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW (2009) Role of adjuvant chemoradiotherapy for ampulla of vater cancer. Int J Radiat Oncol Biol Phys 75:436–441CrossRefPubMed
103.
Palta M, Patel P, Broadwater G, Willett C, Pepek J, Tyler D, Zafar SY, Uronis H, Hurwitz H, White R, Czito B (2012) Carcinoma of the ampulla of vater: patterns of failure following resection and benefit of chemoradiotherapy. Ann Surg Oncol 19:1535–1540CrossRefPubMed
104.
Jabbour SK, Mulvihill D (2014) Defining the role of adjuvant therapy: ampullary and duodenal adenocarcinoma. Semin Radiat Oncol 24:85–93CrossRefPubMed
105.
Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Ghaneh P, Halloran CM, Lerch MM, Oláh A, Rawcliffe CL, Verbeke CS, Campbell F, Büchler MW, European Study Group for Pancreatic Cancer (2012) Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA 308:147–156
106.
Hechtman JF, Liu W, Sadowska J, Zhen L, Borsu L, Arcila ME, Won HH, Shah RH, Berger MF, Vakiani E, Shia J, Klimstra DS (2015) Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of erbb2 (her2). Mod Pathol 28:1123–1129CrossRefPubMedPubMedCentral
107.
Alvi MA, McArt DG, Kelly P, Fuchs MA, Alderdice M, McCabe C, Bingham V, McGready C, Tripathi S, Emmert-Streib F, Loughrey MB, McQuaid S, Maxwell P, Hamilton PW, Turkington R, James JA, Wilson RH, Salto-Tellez M (2015) Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with potential for clinical utility. Oncotarget 6:20863–20874CrossRefPubMedPubMedCentral
Metadaten
Titel
Primary small bowel adenomas and adenocarcinomas—recent advances
verfasst von
Aoife Maguire
Kieran Sheahan
Publikationsdatum
11.07.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Virchows Archiv / Ausgabe 3/2018
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-018-2400-7

Weitere Artikel der Ausgabe 3/2018

Virchows Archiv 3/2018 Zur Ausgabe

Original Article

Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile

Brief Report

Comparison of targeted next generation sequencing (NGS) versus isolated BRAF V600E analysis in patients with metastatic melanoma

News

In this issue

Brief Report

Extra-osseous Ewing sarcoma of the pancreas: case report with radiologic, pathologic, and molecular correlation, and brief review of the literature

Correction

Correction to: Correction to: The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer

Letter to the Editor

Aberrant expression of TdT in seminomatous germ cell neoplasia

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Zielgerichtete Therapie Leitthema

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …